REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > (o=)n(=o)-o-c Containing (e.g., Nitrate Ester, Etc.) (o=)n(=o)-o-c Containing (e.g., Nitrate Ester, Etc.)(o=)n(=o)-o-c Containing (e.g., Nitrate Ester, Etc.) patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.12/28/06 - 20060293384 - Isethionyl nitrates and compounds thereof in which the cation M is selected from the group consisting of: hydrogen, alkali metal cations, alkaline earth metal cations, Group III metal cations, transition metal cations, ammonium ions (including organic-substituted ammonium cations), including mixtures of any two or more of the foregoing; R1 and R2 are each independently selected ... 09/28/06 - 20060217439 - Stable no-delivering compounds Disclosed are novel NO-releasing compounds which comprise a stabilized S-nitrosyl group and a free alcohol or a free thiol group. Also disclosed is a method of preparing the NO-releasing compounds. The method comprises reacting a polythiol or a thioalcohol with a nitrosylating agent. Also disclosed are medical devices coated with ... 06/08/06 - 20060122267 - Compositions and methods for attenuating mitochondria-mediated cell injury The present invention relates to a S-nitrosated mitochondria-targeted thiol-based antioxidant prodrug and uses therefore for the prevention or treatment of diseases or conditions associated with mitochondrial dysfunction resulting from changes in the mitochondrial redox environment. When activated, prodrug of the present invention can specifically provide a NO• donor and a ... 02/23/06 - 20060041013 - Alanosine formulations and methods of use Stable liquid formulations of the anti-tumor agent L-alanosine are described. These formulations preferably comprise L-alanosine in an aqueous environment having a basic pH, preferably in the range of about pH 8-9. The alanosine formulations and compositions disclosed herein can be used for various purposes, including the treatment of various cancers, ... 02/09/06 - 20060030622 - Compounds and methods for the treatment of urogenital disorders The present invention provides methods for treating a variety of urogenital disorders, such as, for example, vaginismus, dyspareunia, vulvodynia (including vulvar vestibulitis), interstitial cystitis, nonspecific urethriris (i.e., nonspecific pain and/or burning of the urinary tract) and sexual dysfunctions, such as, for example, female sexual arousal disorders and female sexual orgasmic ... 11/17/05 - 20050256188 - Formulations of anthraquinone derivatives A compound of formula (I): in which A is a C alkylene group with a chain length between NH and N(O)R′R″ of at least 2 carbon atoms and R′ and R″ are each separately selected from C1-4 alkyl groups and C2-4 hydroxyalkyl and C2-4 dihydroxyalkyl groups, or R′ and R″ ... 10/20/05 - 20050234123 - Process At the present invention relates to a new process for the preparation of the (S)-naproxen 4-nitrooxybutyl ester and to new intermediates obtained and used therein. The invention further relates to the use of the new intermediates for the manufacturing of pharmaceutically active compounds such as (S)-naproxen 4-nitrooxybutyl ester. The invention ... 10/06/05 - 20050222253 - Anti-cancer nitro- and thia-fatty acids as an anticancer agent: (a) one or more compounds having the formula NO2-A-B, wherein A is a saturated or unsaturated hydrocarbon chain of 14-26 double bonds, and B is (CH2)m(COOH)n in which n is an integer from 0 to 2 and m is an integer from 0 to 2; or ... 09/01/05 - 20050192346 - Process for making nitric oxide releasing prodrugs of diaryl-2-(5h)-furanones as cyclooxygenase-2 inhibitors which are prodrugs of cyclooxygenase-2 selective inhibitors that convert in vivo to diaryl-2-(5H)-furanones and also liberate nitric oxide in vivo. As such, the compounds made by the present invention may be co-dosed with low-dose aspirin to treat chronic cyclooxygenase-2 mediated diseases or conditions, effectively reduce the risk of thrombotic cardiovascular ... 08/04/05 - 20050171199 - Treatment of overuse tendinopathy using transdermal nitric oxide-generating agents The present invention unexpectedly provides a method for treating acute or chronic tendinopathy by transdermal administration of low-dose glyceryl trinitrate, or other nitric oxide-generating agents. The present invention also provides a method of relieving pain caused by tendinopathy by transdermal administration of low-dose glyceryl trinitrate, or other nitric oxide-generating agents. ... 07/28/05 - 20050165094 - Chemical compounds containing a superoxide scavenger and an organic nitrate or nitrite moiety Compounds for use in the treatment of heart disease include a superoxide scavenger and an organic nitrate or nitrite moiety. The compounds can be represented by the formula (A)n(B)m, in which A is a superoxide scavenger, B is an organic nitrate or organic nitrite moiety, and n and m are ... 06/16/05 - 20050131064 - Therapeutic use of aerosolized nitrosylating agent in cystic fibrosis The present invention is directed to the treatment of cystic fibrosis that involves administration of a nitrosylating agent, such as S-nitrosoglutathione or ethyl nitrite. ... 06/16/05 - 20050131063 - Methods and composition based on discovery of metabolism of nitroglycerin Therapies are for treating patients in need of nitroglycerin therapy and allow increased dosage, postponement of tolerance and preconditioning, without exacerbating or causing hypotension. Methods for determining cross-tolerance, nitroglycerin effectiveness and dose are also disclosed. Composition for intravenous administration of nitroglycerin does not contain ethanol or contains less ethanol than ... ### FreshPatents.com Support |